Assessing the immunogenic and protective potential of different viral vector regimes, in the mouse model of tuberculosis infection

Assessing the immunogenic and protective potential of different viral vector regimes, in the mouse model of tuberculosis infection

Detalhes bibliográficos
Principais autores:	Stylianou, E, Betts, G, Dicks, M, Griffiths, K, Poyntz, H, Mcshane, H
Formato:	Conference item
Publicado em:	2011

Registros relacionados

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
por: Betts, G, et al.
Publicado em: (2012)

Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice
por: Griffiths, K, et al.
Publicado em: (2013)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
por: Gareth Betts, et al.
Publicado em: (2012-01-01)

Th1/Th17 cell induction following vaccination with the novel tuberculosis vaccine MVA85A and their role in Mycobacterium tuberculosis challenge
por: Griffiths, K, et al.
Publicado em: (2011)

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
por: Stylianou, E, et al.
Publicado em: (2015)

Evaluation of immunological mechanisms induced by Mycobacterium avium exposure and the effect upon pre-existing BCG immunity
por: Poyntz, H, et al.
Publicado em: (2011)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis.
por: Poyntz, H, et al.
Publicado em: (2014)

Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb).
por: Marsay, L, et al.
Publicado em: (2013)

Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis
por: Poyntz, H, et al.
Publicado em: (2014)

Mycobacterial growth inhibition in murine splenocytes as a surrogate for protection against Mycobacterium tuberculosis (M. tb)
por: Marsay, L, et al.
Publicado em: (2013)

Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
por: Christopher J. De Voss, et al.
Publicado em: (2025-02-01)

Viral vector delivery of Env trimer immunogens
por: Parks CL, et al.
Publicado em: (2012-09-01)

Uncovering the mechanisms of adenovirus vector immunogenicity
por: Dicks, M, et al.
Publicado em: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
por: Meyer, J, et al.
Publicado em: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
por: Meyer, J, et al.
Publicado em: (2013)

Viral vectors as vaccine platforms: from immunogenicity to impact
por: Ewer (nee Russell), K, et al.
Publicado em: (2016)

Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.
por: Biswas, S, et al.
Publicado em: (2011)

Evaluation of the immunological mechanisms induced by mycobacteria and the potential effect this may have on immunity induced by tuberculosis vaccines
por: Poyntz, HC
Publicado em: (2012)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
por: Mcshane, H, et al.
Publicado em: (2001)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
por: Rowland, R, et al.
Publicado em: (2013)

Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.
por: Sumi Biswas, et al.
Publicado em: (2011-01-01)

Improved systems for generating and evaluating adenovirus vaccine vectors reveal differences in immunogenicity between vectors of different adenoviral species
por: Dicks, M, et al.
Publicado em: (2011)

Immunogenicity and Protective Efficacy of a Recombinant Pichinde Viral-Vectored Vaccine Expressing Influenza Virus Hemagglutinin Antigen in Pigs
por: Sushmita Kumari, et al.
Publicado em: (2022-08-01)

Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-riming and boosting with adenovirus or protein based vaccines
por: Dean, G, et al.
Publicado em: (2014)

Assessment of immunogenicity and neutralisation efficacy of viral-vectored vaccines against Chikungunya virus
por: López-Camacho, C, et al.
Publicado em: (2019)

Fighting Fire with Fire: Immunogenicity of Viral Vectored Vaccines against COVID-19
por: Aiquan Chang, et al.
Publicado em: (2022-02-01)

Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus
por: César López-Camacho, et al.
Publicado em: (2019-04-01)

Protection by Persuasion: International Cooperation in the Refugee Regime
por: Betts, A
Publicado em: (2010)

Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines.
por: Dean, G, et al.
Publicado em: (2014)

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
por: Dicks, M, et al.
Publicado em: (2012)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
por: Sander, C, et al.
Publicado em: (2009)

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis.
por: Vordermeier, H, et al.
Publicado em: (2009)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
por: White, A, et al.
Publicado em: (2013)

Erratum: Viral booster vaccines improve mycobacterium bovis BCG-induced protection against bovine tuberculosis
por: Vordermeier, H, et al.
Publicado em: (2011)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
por: Goonetilleke, N, et al.
Publicado em: (2003)

Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles
por: Tingfeng Wang, et al.
Publicado em: (2024-12-01)

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
por: Stylianou, E, et al.
Publicado em: (2019)

The Use of Viral Vectors for Gene Therapy and Vaccination in Tuberculosis
por: Dulce Mata-Espinosa, et al.
Publicado em: (2023-10-01)

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
por: Brookes, R, et al.
Publicado em: (2008)

Evaluation of Duration of Immunogenicity and Protective Efficacy of Improved Influenza Viral Vector–Based Brucella abortus Vaccine Against Brucella melitensis Infection in Sheep and Goats
por: Aigerim Mailybayeva, et al.
Publicado em: (2020-02-01)